

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Frazier Life Sciences VIII, L.P.</u> <hr/> (Last) (First) (Middle) 601 UNION STREET, SUITE 3200 <hr/> (Street) SEATTLE WA 98101 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Entasis Therapeutics Holdings Inc. [ETTX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 01/09/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/09/2020		S		50,000	D	\$5.0002 ⁽¹⁾	1,299,953	D ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person *

Frazier Life Sciences VIII, L.P.

(Last) (First) (Middle)

601 UNION STREET, SUITE 3200

(Street)

SEATTLE WA 98101

(City) (State) (Zip)

1. Name and Address of Reporting Person *

Topper James N

(Last) (First) (Middle)

C/O ENTASIS THERAPEUTICS HOLDINGS INC.
35 GATEHOUSE DRIVE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

1. Name and Address of Reporting Person *		
FHM LIFE SCIENCES VIII, L.P.		
(Last)	(First)	(Middle)
601 UNION STREET, SUITE 3200		
(Street)		
SEATTLE	WA	98101
(City) (State) (Zip)		
1. Name and Address of Reporting Person *		
FHM LIFE SCIENCES VIII, L.L.C.		
(Last)	(First)	(Middle)
601 UNION STREET, SUITE 3200		
(Street)		
SEATTLE	WA	98101
(City) (State) (Zip)		
1. Name and Address of Reporting Person *		
Heron Patrick J		
(Last)	(First)	(Middle)
601 UNION STREET, SUITE 3200		
(Street)		
SEATTLE	WA	98101
(City) (State) (Zip)		

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$5.00 to \$5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1 to this Form 4

2. The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"), FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. James Topper and Patrick Heron are the sole managing members of FHM LLC. Mr. Heron, Mr. Topper, FHM LP and FHM LLC disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his or its pecuniary interest therein, if any.

Remarks:

[Frazier Life Sciences VIII, L.P.](#)
[By: FHM Life Sciences VIII,](#)
[L.P. Its: general partner By:](#) 01/13/2020
[FHM Life Sciences VIII,](#)
[L.L.C. Its: general partner, By:](#)
[/s/ Steve Bailey](#)
[/s/ Steve Bailey, Attorney-in-](#) 01/13/2020
[Fact for James N. Topper](#)
[FHM Life Sciences VIII, L.P.](#)
[By: FHM Life Sciences VIII,](#) 01/13/2020
[L.L.C. Its: general partner By:](#)
[/s/ Steve Bailey](#)
[FHM Life Sciences VIII,](#) 01/13/2020
[L.L.C. By: /s/ Steve Bailey](#)
[/s/ Steve Bailey, Attorney-in-](#) 01/13/2020
[Fact for Patrick J. Heron](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.